Zhenghai Bio: Shareholder Longwood's Reduction Reaches 1% Integer Multiple, Shareholding Drops to 6.88%

Image Source: Announcement by Zhenghai Bio-tech Co., Ltd. Regarding Share Reduction by Shareholder Holding Over 5% Reaching an Integer Multiple of 1%

DentalGoodNews | April 3, 2026, Yantai Zhenghai Bio-tech Co., Ltd. (hereinafter referred to as "Zhenghai Bio-tech") released the "Announcement Regarding Share Reduction by Shareholder Holding Over 5% Reaching an Integer Multiple of 1%". The announcement shows that Longwood Biotechnologies Inc. (hereinafter referred to as "Longwood"), a shareholder holding over 5% of the company's shares, cumulatively reduced its holdings of 1,431,700 shares of the company through centralized auction trading from March 24 to April 2, 2026, accounting for 0.79% of the company's total share capital.

After this change in equity, the number of Zhenghai Bio-tech shares held by Longwood decreased from 13,811,900 shares to 12,380,200 shares, and its shareholding ratio dropped from 7.67% to 6.88%. This change in shareholding ratio reached an integer multiple of 1%. Public information shows that Longwood was once the second-largest shareholder of Zhenghai Bio-tech. Its executive director, Dong Qun, once served as Vice Chairman of Zhenghai Bio-tech and left the position in August 2025.

Zhenghai Bio-tech is a national high-tech enterprise focusing on the field of regenerative medicine. Its main products include Dental Restoration membranes, absorbable dura mater (spinal) patches, and active biological bone. According to a previous report by DENTALGOODNEWS (Leading Dental Industry Media, DGN), Longwood once proposed a plan in July 2022 to reduce its holdings by no more than 7.2 million shares (approximately 4% of the total share capital). At that time, Zhenghai Bio-tech's stock price rose by about 70% within two months.

According to the pre-disclosure announcement released by the company on February 27, 2026, Longwood plans to reduce its holdings of the company's shares by no more than 3.6 million shares (approximately 2% of the total share capital) within 3 months through centralized auction trading and block trading. As of now, this share reduction plan has not been fully implemented. Zhenghai Bio-tech stated that this reduction will not lead to a change in the company's control rights, nor will it have a significant impact on the company's continuous operation.

In terms of performance, Zhenghai Bio-tech achieved operating revenue of 364 million yuan in 2025, a year-on-year increase of 0.25%. However, the Net Profit Attributable to Shareholders of the Parent Company was 82.41 million yuan, a year-on-year decrease of 38.79%. Affected by market competition and the VBP policy, the revenue of its core product, the Dental Restoration membrane, declined by 15.82% in 2025.